SIP
GALT icon

Stoneridge Investment Partners’s Galectin Therapeutics GALT Stock Holding History

Stoneridge Investment Partners’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-28,276
Closed -$46K – 301
2015
Q4 		$46K Sell
28,276
-5,517
-16% -$12.6K 0.01% 274
2015
Q3 		$79K Sell
33,793
-1,506
-4% -$3.55K 0.01% 276
2015
Q2 		$96K Buy
35,299
+9,498
+37% +$28.6K 0.01% 268
2015
Q1 		$86K Buy
25,801
+706
+3% +$2.52K 0.01% 260
2014
Q4 		$87K Buy
+25,095
New +$111K 0.01% 248

Other funds holding GALT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return

Stoneridge Investment Partners's GALT Position: Q1 2016 in Review

Stoneridge Investment Partners sold out of Galectin Therapeutics (GALT) in Q1 2016, closing a stake of 28,276 shares — an estimated $46K sold.

Stoneridge Investment Partners first reported a position in GALT in Q4 2014 and held it in 5 quarters. The position peaked at $96K in Q2 2015. 50 funds tracked by Wall St. Rank hold GALT as of Q1 2016.

  • Stoneridge Investment Partners reported no remaining Galectin Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Stoneridge Investment Partners sold 28,276 Galectin Therapeutics shares in Q1 2016, an estimated $46K.
  • Stoneridge Investment Partners first reported a position in Galectin Therapeutics in Q4 2014 and held it in 5 quarters.
  • Stoneridge Investment Partners's Galectin Therapeutics position peaked at $96K in Q2 2015.
  • 50 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2016.

Based on Stoneridge Investment Partners's 13F filing for Q1 2016, filed 29 Apr 2016.